CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. [ Read More ]
The intrinsic value of one CDX stock under the Base Case scenario is 0.018 AUD. Compared to the current market price of 0.135 AUD, Cardiex Ltd is Overvalued by 87%.
Intrinsic Value History...
Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.